Discovery of Novel Delta Opioid Receptor (DOR) Inverse Agonist and Irreversible (Non-Competitive) Antagonists

• Published in: Molecules (Basel, Switzerland) Switzerland), 2021-11, Vol.26 (21), p.6693
• Main Authors: Tanguturi, Parthasaradhireddy, Pathak, Vibha, Zhang, Sixue, Moukha-Chafiq, Omar, Augelli-Szafran, Corinne E, Streicher, John M
• Format: Article
• Language: English
• Subjects: Affinity; Analgesics, Opioid - chemical synthesis; Analgesics, Opioid - chemistry; Analgesics, Opioid - pharmacology; Antagonists; Binding; Binding sites; Binding, Competitive; Biology; Chemical compounds; Chemistry Techniques, Synthetic; Competition; delta opioid receptor; Drug Discovery - methods; Humans; In vivo methods and tests; inverse agonist; Inverse agonists; irreversible antagonist; Ligands; molecular pharmacology; Molecular Structure; Naltrindole; Narcotics; non-competitive antagonist; Opioid receptors (type delta); Pain; Pharmacology; Protein Binding; Receptors, Opioid, delta - agonists; Receptors, Opioid, delta - chemistry; Selectivity; Structure-Activity Relationship
• ISSN: 1420-3049; 1420-3049
• DOI: 10.3390/molecules26216693

The delta opioid receptor (DOR) is a crucial receptor system that regulates pain, mood, anxiety, and similar mental states. DOR agonists, such as SNC80, and DOR-neutral antagonists, such as naltrindole, were developed to investigate the DOR in vivo and as potential therapeutics for pain and depression. However, few inverse agonists and non-competitive/irreversible antagonists have been developed, and none are widely available. This leaves a gap in our pharmacological toolbox and limits our ability to investigate the biology of this receptor. Thus, we designed and synthesized the novel compounds SRI-9342 as an irreversible antagonist and SRI-45128 as an inverse agonist. These compounds were then evaluated in vitro for their binding affinity by radioligand binding, their functional activity by S-GTPγS coupling, and their cAMP accumulation in cells expressing the human DOR. Both compounds demonstrated high binding affinity and selectivity at the DOR, and both displayed their hypothesized molecular pharmacology of irreversible antagonism (SRI-9342) or inverse agonism (SRI-45128). Together, these results demonstrate that we have successfully designed new inverse agonists and irreversible antagonists of the DOR based on a novel chemical scaffold. These new compounds will provide new tools to investigate the biology of the DOR or even new potential therapeutics.